2019
Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics
Bitton G, Rom V, Hadelsberg U, Raz I, Cengiz E, Weinzimer S, Tamborlane WV. Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. Journal Of Diabetes Science And Technology 2019, 13: 1123-1128. PMID: 31067999, PMCID: PMC6835184, DOI: 10.1177/1932296819842151.Peer-Reviewed Original ResearchConceptsInjection siteGlucose levelsSerum glucoseSubcutaneous depotMultiple daily insulin injectionsOvernight glucose levelsDaily insulin injectionsBlood glucose controlType 1 diabetesSensor glucose levelsInsulin infusion rateDL increaseInsulin glargineSerum insulinGlucose controlMDI therapyInsulin injectionsInsulin concentrationsPharmacodynamic studiesInfusion rateSkin warmingSeparate daysControl dayRate of absorptionRandom order
2016
Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
Sherr JL, Ruedy KJ, Foster NC, Piché CA, Dulude H, Rickels MR, Tamborlane WV, Bethin KE, DiMeglio LA, Fox LA, Wadwa RP, Schatz DA, Nathan BM, Marcovina SM, Rampakakis E, Meng L, Beck RW. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes. Diabetes Care 2016, 39: 555-562. PMID: 26884472, PMCID: PMC4806770, DOI: 10.2337/dc15-1606.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentBlood GlucoseChildChild, PreschoolCohort StudiesCross-Over StudiesDiabetes Mellitus, Type 1Dose-Response Relationship, DrugDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleGlucagonHumansHypoglycemiaInjections, IntramuscularInsulinMaleNauseaPowdersConceptsIntramuscular glucagonType 1 diabetesIntranasal dosesIntranasal glucagonYounger cohortsWeight-based doseMin of dosingTreatment of hypoglycemiaDose-response relationshipTransient nauseaDl riseSevere hypoglycemiaGlucagon levelsIntranasal doseClinical centersPlasma glucosePharmacodynamic studiesHospital settingGlucagon preparationPotential efficacyGlucagonType 1Adverse effectsCohortAge range